Aeris Therapeutics is engaged in the development and commercialization of novel therapies for patients with emphysema and other lung diseases.

Aeris Therapeutics lead product is the AeriSeal™ System for Lung Volume Reduction for the treatment of advanced emphysema.

Emphysema affects approximately 4 million patients in the United States and as many as 60 million patients worldwide. 

The AeriSeal™ System for Lung Volume Reduction

CAUTION: The AeriSeal System for Lung Volume Reduction is an investigational device and is limited by Federal (or United States) law to investigational use.